On August 9, 2022 Kureha Corporation reported that Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2023 (Press release, Kureha Corporation, AUG 9, 2022, View Source [SID1234617844])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2023 (From April 1, 2022 to June 30, 2022)
(1) Consolidated Operating Results
(2) Consolidated Financial Position2. Dividends

2. Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2023 (From April 1, 2022 to March 31, 2023)

* This quarterly financial summary is outside the scope of review by certified public accountants or audit corporations. * Note to ensure proper use of financial forecasts, and other noteworthy matters All forecasts and forward-looking statements in this report are based on information currently available to the Company and assumptions that are deemed to be reasonable, but Kureha Corporation does not guarantee the achievement of these forecasts. Actual results may differ significantly as a consequence of numerous factors. For more information regarding the assumptions and terms the Company applied when formulating earnings forecasts and precautions that should be taken when utilizing these earnings forecasts, please refer to "(3) Outlook for the Fiscal Year Ending March 31, 2023 and beyond" included under the section "1. Overview of Operating Results and Outlook" on page 3 of the attached document.